Market Intelligence, Clinical Progress, and High-Purity Reagents for Targeted Conditioning, Autoimmune Disease, and Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CD45 isoform-specific drug discovery. The table below lists available components, covering pan-CD45, isoform-specific RA/RO, gene delivery, benchmark antibodies, validation tools, and cross-selling targets.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Pan Antigen | CD45 ECD-Fc Fusion (All Isoforms) HEK293 expressed, >95% purity, Endotoxin <1 EU/µg. Sequence Verified. |
View CD45 Products |
| Isoform RA | CD45RA ECD-Fc (Exon 4 Retained) Distinct from RO isoform, high purity, sequence verified. |
View CD45RA Products |
| Isoform RO | CD45RO ECD-Fc (Exon 4-6 Excluded) Memory T cell marker, theoretical MW verified. |
View CD45RO Products |
| Gene Delivery | PTPRC Lentivirus Premade Particles / Promise-ORF Full-length ORF for stable cell line construction. |
View PTPRC Products |
| Benchmark Ab | Anti-CD45 Recombinant Antibody (Functional Clone / BC8 Reference) Recombinant positive control for binding, ADC, and radioconjugate assays. |
View CD45 Products |
| Validator | PTPRC siRNA Set For knockdown verification and specificity control. |
View PTPRC Products |
| Related Target: CD3E | CD3 Epsilon TCR Complex Partner, Signal Modulation. |
View CD3E Products |
| Related Target: LCK | LCK Kinase Direct Substrate of CD45 Phosphatase Activity. |
View LCK Products |
| Related Target: CD117/c-Kit | Synergistic target for non-genotoxic hematopoietic stem cell conditioning. | View CD117 Products |
| Related Target: CD3 | Core pathway partner for T-cell engager and bispecific development. | View CD3 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Specificity (CD45RA vs CD45RO) | Separate CD45RA and CD45RO ECD proteins with verified splice variant sequences; no cross-contamination. |
| Glycosylation-Dependent Epitopes | HEK293 expressed (native glycosylation) ensures proper tertiary structure and physiological glycan profiles. |
| Internalization & ADC Payload Delivery | High-purity ECD-Fc for binding kinetics; Lentivirus stable cell lines for flow-cytometry internalization readouts. |
| Cross-species Evaluation (Cyno/Mouse) | Human, mouse, and cynomolgus ortholog proteins available with >95% sequence homology. |
| Assay Specificity & Controls | Clinical benchmark antibodies (BC8 reference) and validated siRNA included for target confirmation. |
Live CD45 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials (CD45 conditioning)
- ➤ Latest ADC & Radioconjugate Research
- ➤ Recent Patent Filings (Isoform-specific)
Global Clinical Landscape & Future Outlook
The race for CD45-targeted therapeutics is intensifying, with major players shifting focus from pan-lymphodepletion to isoform-specific immune conditioning and non-genotoxic hematopoietic conditioning. First-generation radioconjugates (e.g., Iomab-B, Actinium Pharmaceuticals) are advancing through Phase III for stem-cell transplant conditioning in AML/MDS. Concurrently, CD45 ADCs (Magenta Biosciences MGTA-117) are approaching Phase II for autoimmune indications. The next wave of R&D targets precise isoform-specific depletion (CD45RA/RO) to reset autoimmune environments while preserving naive immunity, and safer conditioning regimens using radioimmunotherapy or ADCs with optimized internalization kinetics.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need |
|---|---|---|---|
| Radioconjugate | Actinium Pharmaceuticals (Iomab-B) | HSCT Conditioning (AML, MDS) | Internalization & cell-based killing assays; need full-length Lentivirus stable lines. |
| ADC | Magenta Biosciences (MGTA-117), NCI / Academic | Autoimmune Disease, Leukemia, HSCT Conditioning | Isoform binding specificity; high-purity ECD-Fc for early screening; pH-dependent release assays. |
| Isoform-Specific mAb | Academic / Early Biotech | Memory T Cell Depletion, GvHD, SLE | CD45RA vs CD45RO selectivity panel; strictly verified by mass spec. |
| Bispecific T-Cell Engager | Emerging Biotech | Hematological Malignancies | Heterodimer validation; cross-reactive antibodies and stable cell lines via Lentivirus. |
| CAR-T Engineering | Cell Therapy Developers | Solid Tumors (Fratricide Prevention) | CD45 knockdown validation using PTPRC siRNA; stable knockout cell lines. |
Functional & Mutational Context (From UniProt P08575)
CD45 is encoded by the PTPRC gene. Its functional domains include Fibronectin type-III 1, Fibronectin type-III 2, and Tyrosine-protein phosphatase 1. Key reported mutations include dbSNP:rs4915154, a somatic mutation in a breast cancer sample, and dbSNP:rs2230606. These variations influence epitope recognition and drug resistance mechanisms, underscoring the need for high-quality mutant proteins and isoform-specific reagents.